More information: Jacqueline Fátima Martins de Almeida et al, Molecular aspects of Angelman Syndrome: Defining the new path forward, Biomolecules and Biomedicine (2025). DOI: 10.17305/bb.2025.11724 ...

NOVATO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that it has ...

One of the best-understood epigenetic mechanisms—genomic imprinting—explains much about both sleep and the brain.

Angelman syndrome is a rare neurogenetic disorder affecting approximately 1 in 15,000 live births or 500,000 people globally. It results from the loss of function of the UBE3A gene located on the ...

Colin Farrell opened up to PEOPLE about his son James, who was diagnosed with Angelman syndrome. Here’s what to know about the rare neurogenetic disorder that affects 1 in 15,000 people.

Ionis Pharmaceuticals is looking ahead to a Phase 3 study for an antisense medicine it is developing to treat Angelman syndrome, a rare neurodevelopmental disorder with no FDA-approved therapies.

It is named after Dr. Harry Angelman, and English physician who first described the condition in 1965. The disorder is rare, affecting around one in 12,000 to 20,000 people, the Cleveland Clinic ...

For the first time, Colin Farrell has opened up his home and talked in-depth about life with his son James, who has Angelman syndrome. James was just a toddler when he was diagnosed with the rare ...

Actor Colin Farrell is launching a new foundation to raise awareness of a rare genetic condition called Angelman syndrome, so that his son and others with the disorder will have more support and ...

Angelman syndrome affects an estimated 15,000 to 500,000 people worldwide. ... imprinting defects, point mutations in UBE3A, and cases with unknown origins.

The actor’s son James has Angelman syndrome, a rare neurogenetic disorder. The Colin Farrell Foundation aims to raise awareness about intellectual disability.